Previous 10 | Next 10 |
2024-04-16 09:00:05 ET David Risinger from Leerink Partners issued a price target of $47.00 for ANAB on 2024-04-16 07:27:00. The adjusted price target was set to $47.00. At the time of the announcement, ANAB was trading at $21.27. The overall price target consensus is at...
2024-04-12 19:00:50 ET Many stocks were wobbly over the past few trading days, but we can't say that about biotech AnaptysBio (NASDAQ: ANAB) . The company's shares closed the week almost 8% higher in price, according to data compiled by S&P Global Market Intelligence , large...
2024-04-09 16:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-30 18:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-28 16:52:13 ET Gainers: Semtech Corporation ( SMTC ) +10% . Zentalis Pharmaceuticals ( ZNTL ) +9% . Sagimet Biosciences ( SGMT ) +5% . Photronics ( PLAB ) +5% . James River Group Holdings ( JRVR ) +4% . Losers...
2024-03-25 17:15:09 ET Gainers: Stoke Therapeutics ( STOK ) +87% . AnaptysBio ( ANAB ) +8% . Amneal Pharmaceuticals ( AMRX ) +6% . Omega Therapeutics ( OMGA ) +5% . MoneyHero ( MNY ) +5% . Losers: Ocular Therapeutix...
2024-03-12 13:11:55 ET More on AnaptysBio Stifel starts AnaptysBio at buy, cites upcoming catalysts AnaptysBio gains as Piper Sandler starts at Overweight on catalyst path Seeking Alpha’s Quant Rating on AnaptysBio Historical earnings data for AnaptysB...
2024-03-12 08:30:01 ET Wedbush analyst issues OUTPERFORM recommendation for ANAB on March 12, 2024 06:04AM ET. The previous analyst recommendation was Neutral. ANAB was trading at $23.35 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Cu...
2024-03-11 16:52:03 ET More on AnaptysBio Stifel starts AnaptysBio at buy, cites upcoming catalysts AnaptysBio gains as Piper Sandler starts at Overweight on catalyst path Seeking Alpha’s Quant Rating on AnaptysBio Historical earnings data for AnaptysB...
Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist, with top-line data anticipated by year-end 2024 Enrollment ongoing for global Phase 2b trial to treat rheumatoid arthritis (RA) and global Phase 2 trial to treat ulcerative colitis (UC)...
News, Short Squeeze, Breakout and More Instantly...
2024-05-10 18:15:02 ET Wells Fargo analyst issues BUY recommendation for ANAB on May 10, 2024 05:01PM ET. The previous analyst recommendation was Buy. ANAB was trading at $23.41 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current ana...
Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist; reiterating top-line data anticipated by year-end 2024 Enrollment ongoing for global Phase 2b trial to treat rheumatoid arthritis (RA) and global Phase 2 trial to treat ulcerative colit...
All eight patients from GEMINI-1 who responded to a single intravenous (IV) imsidolimab dose and were subsequently re-randomized to monthly subcutaneous (SC) maintenance dosing of imsidolimab in GEMINI-2 through at least 24 weeks maintained clear to almost clear skin and none experienced a flare ...